Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
3(16%)
Results Posted
13%(1 trials)

Phase Distribution

Ph phase_2
3
16%
Ph early_phase_1
2
11%
Ph not_applicable
1
5%
Ph phase_1
11
58%

Phase Distribution

13

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution17 total trials
Early Phase 1First-in-human
2(11.8%)
Phase 1Safety & dosage
11(64.7%)
Phase 2Efficacy & side effects
3(17.6%)
N/ANon-phased studies
1(5.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

3

trials recruiting

Total Trials

19

all time

Status Distribution
Active(8)
Completed(8)
Terminated(1)
Other(2)

Detailed Status

Completed8
Not yet recruiting4
Recruiting3
Suspended2
Withdrawn1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
19
Active
3
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 12 (11.8%)
Phase 111 (64.7%)
Phase 23 (17.6%)
N/A1 (5.9%)

Trials by Status

completed842%
suspended211%
recruiting316%
not_yet_recruiting421%
withdrawn15%
enrolling_by_invitation15%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT07533591Early Phase 1

Clinical Study of Chemogenetic Gene Therapy With AAV Virus for Parkinson's Disease Using Stereotactic Surgery in the Subthalamic Nucleus

Not Yet Recruiting
NCT07364357Phase 1

A Phase I Study of CREPT-618 in Locally Advanced HCC

Recruiting
NCT07011771Phase 1

A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease

Suspended
NCT06983158Phase 1

A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy

Suspended
NCT05152823Phase 1

Gene Therapy for IGHMBP2-Related Diseases

Enrolling By Invitation
NCT07085195Early Phase 1

A Clinical Study of the Safety and Efficacy of Chemogenetics Therapy in the Treatment of Parkinson's Disease

Not Yet Recruiting
NCT04797260Not Applicable

Phase I/II Clinical Trial Stem Cell Gene Therapy in RAG1-Deficient SCID

Recruiting
NCT04418414Phase 1

Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A

Not Yet Recruiting
NCT00598481Phase 2

ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID

Completed
NCT05991336

Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy

Recruiting
NCT05815004Phase 2

An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3

Withdrawn
NCT01395641Phase 1

A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC

Completed
NCT04883710

The World Federation of Hemophilia Gene Therapy Registry

Not Yet Recruiting
NCT00002824Phase 1

Gene Therapy in Treating Patients With Primary Brain Tumors

Completed
NCT01172964Phase 1

A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas

Completed
NCT00005796Phase 1

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors

Completed
NCT00006033Phase 2

Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer

Completed
NCT00001735Phase 1

Gene Therapy for Gyrate Atrophy

Completed
NCT00004809Phase 1

Phase I Study of Ex Vivo Liver-Directed Gene Therapy for Familial Hypercholesterolemia

Completed

All 19 trials loaded

Drug Details

Intervention Type
GENETIC
Total Trials
19